相似文献
1
Effects of recombinant erythropoietin on breast cancer-initiating cells.
Neoplasia. 2007 Dec;9(12):1122-9. doi: 10.1593/neo.07694.
2
HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer.
J Steroid Biochem Mol Biol. 2015 Apr;148:111-21. doi: 10.1016/j.jsbmb.2014.12.013. Epub 2014 Dec 23.
3
Mammary stem cells and breast cancer--role of Notch signalling.
Stem Cell Rev. 2007 Jun;3(2):169-75. doi: 10.1007/s12015-007-0023-5.
4
EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation.
Biochem Biophys Res Commun. 2014 Feb 28;445(1):163-9. doi: 10.1016/j.bbrc.2014.01.165. Epub 2014 Feb 3.
5
Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation.
Blood. 2003 May 1;101(9):3436-43. doi: 10.1182/blood-2002-07-2332. Epub 2002 Dec 27.
6
Src transduces erythropoietin-induced differentiation signals through phosphatidylinositol 3-kinase.
EMBO J. 2001 Oct 15;20(20):5666-77. doi: 10.1093/emboj/20.20.5666.
7
Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.
J Hematol Oncol. 2016 Aug 31;9(1):75. doi: 10.1186/s13045-016-0306-x.
8
Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer.
Clin Cancer Res. 2009 Sep 1;15(17):5552-9. doi: 10.1158/1078-0432.CCR-08-3014. Epub 2009 Aug 25.
9
Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies.
Cell Death Dis. 2013 Oct 3;4(10):e828. doi: 10.1038/cddis.2013.337.
10
The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation.
J Natl Cancer Inst. 2006 Dec 20;98(24):1777-85. doi: 10.1093/jnci/djj495.
引用本文的文献
1
Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer.
Sci Adv. 2024 Nov;10(44):eado8275. doi: 10.1126/sciadv.ado8275. Epub 2024 Oct 30.
2
Novel Anti-Cancer Stem Cell Compounds: A Comprehensive Review.
Pharmaceutics. 2024 Aug 1;16(8):1024. doi: 10.3390/pharmaceutics16081024.
3
Recurrent Conjunctival Squamous Cell Carcinoma and Intraocular Tumor Extension after Topical Erythropoietin: A Case Report.
Case Rep Ophthalmol. 2022 Feb 14;13(1):89-95. doi: 10.1159/000521735. eCollection 2022 Jan-Apr.
4
Notch Signaling in Vascular Endothelial Cells, Angiogenesis, and Tumor Progression: An Update and Prospective.
Front Cell Dev Biol. 2021 Feb 16;9:642352. doi: 10.3389/fcell.2021.642352. eCollection 2021.
5
Unlocking the Secrets of Cancer Stem Cells with γ-Secretase Inhibitors: A Novel Anticancer Strategy.
Molecules. 2021 Feb 12;26(4):972. doi: 10.3390/molecules26040972.
6
Cancer Stem Cells, ? The Notch Signaling Pathway in Tumor Initiation and Progression.
Cells. 2020 Aug 11;9(8):1879. doi: 10.3390/cells9081879.
7
Serum erythropoietin levels, breast cancer and breast cancer-initiating cells.
Breast Cancer Res. 2019 Jan 30;21(1):17. doi: 10.1186/s13058-019-1100-9.
8
Recombinant human erythropoietin stimulates melanoma tumor growth through activation of initiation factor eIF4E.
Oncotarget. 2017 May 2;8(18):30317-30327. doi: 10.18632/oncotarget.16331.
9
NOTCH1 is a poor prognostic factor for breast cancer and is associated with breast cancer stem cells.
Onco Targets Ther. 2016 Nov 7;9:6865-6871. doi: 10.2147/OTT.S109606. eCollection 2016.
10
Association between FBP1 and hypoxia-related gene expression in clear cell renal cell carcinoma.
Oncol Lett. 2016 Jun;11(6):4095-4098. doi: 10.3892/ol.2016.4504. Epub 2016 Apr 27.
本文引用的文献
1
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
J Clin Oncol. 2007 Mar 20;25(9):1027-32. doi: 10.1200/JCO.2006.07.1514. Epub 2007 Feb 20.
2
Identification of pancreatic cancer stem cells.
Cancer Res. 2007 Feb 1;67(3):1030-7. doi: 10.1158/0008-5472.CAN-06-2030.
3
Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line.
J Cell Sci. 2007 Feb 1;120(Pt 3):468-77. doi: 10.1242/jcs.03348. Epub 2007 Jan 16.
4
Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.
Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8. doi: 10.1073/pnas.0610117104. Epub 2007 Jan 8.
5
WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells.
Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):618-23. doi: 10.1073/pnas.0606599104. Epub 2007 Jan 3.
6
The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation.
J Natl Cancer Inst. 2006 Dec 20;98(24):1777-85. doi: 10.1093/jnci/djj495.
7
Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity.
Stem Cells. 2007 Mar;25(3):718-22. doi: 10.1634/stemcells.2006-0687. Epub 2006 Nov 16.
8
CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis.
Breast Cancer Res. 2006;8(5):R59. doi: 10.1186/bcr1610.
9
Do erythropoietin receptors on cancer cells explain unexpected clinical findings?
J Clin Oncol. 2006 Oct 10;24(29):4708-13. doi: 10.1200/JCO.2006.06.2737.
10
Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.
Clin Cancer Res. 2006 Oct 1;12(19):5615-21. doi: 10.1158/1078-0432.CCR-06-0169.
Zotero 插件